CCNE1 and ovarian cancer: The anticancer effect of Cyclin E1/Cdk2 complexes has been extensively concerned in a variety of tumors, including ovarian cancer (Kanska et al., 2016), liver cancer (Bisteau et al., 2014; Ehedego et al., 2018), and so on (Fang et al., 2016).